Victor Sandor - Jan 3, 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Director
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 04:11 PM
Previous filing
Oct 14, 2021
Next filing
Jun 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Director Stock Option (Right to Buy) Award $0 +11.2K $0.00 11.2K Jan 3, 2022 Common Stock 11.2K $13.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/12 of the total shares monthly beginning on November 13, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.